(P30-004-24) Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users: Implementation of the CRAVE Study Protocol

Objectives: This CRAVE research study aims to evaluate the impact of GLP-1 receptor agonist (GLP-1RA) medications, specifically semaglutide and tirzepatide, on food cravings and diet quality scores among individuals diagnosed with overweight and/or obesity.

Methods: Conducted over 24 weeks, this prospective single-arm efficacy outcomes study, in collaboration with Seen Medical Group of MA at Knownwell Health Clinic, aims to enroll up to 100 adult participants who are prescribed either semaglutide or tirzepatide. Participants who elect to enroll in our study will receive validated questionnaires and dietary food records at 0, 12, and 24 weeks to assess dietary quality, disordered eating, food cravings, and hunger changes. This analysis seeks to evaluate the potential impact of GLP-1RA medication on various psychosocial domains associated with weight loss and nutrition outcomes. Remarkably, to date, no publications exist on the dietary quality of GLP1-RAs, emphasizing the novelty and importance of our current research endeavor.

Results: N/A

Conclusions: The anticipated results of this study hold the potential to reveal the complex relationship between GLP1-RAs and psychosocial factors, offering an understanding of the medication's collective impact on weight management. Such insights could revolutionize obesity management, informing personalized interventions and advancing our approach towards obesity care, emphasizing the significance of nutrition lifestyle interventions, particularly in virtual healthcare delivery settings.

Funding Sources: Henry A Jastro Research Award College of Ag. & Environmental Sciences UC Davis